![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon alpha-2a and Ribavirin in the PILLAR Study
|
|
|
Reported by Jules Levin
EASL 2011 Berlin March 30-April 3
Jeroen AERSSENS,1 Greg FANNING,2 Annick SCHOLLIERS,3
Oliver LENZ,4 Monika PEETERS,5 Goedele DE SMEDT,6
Michael W FRIED7
1Department of Translational Genomics & Genetics; 2Department of Infectious Disease and Vaccines; 3Department of Enabling Biology; 4Department of Clinical Virology; 5Department of Statistics; 6Department of Clinical Development, Tibotec, Beerse, Belgium; 7University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
![croi1.gif](../images/040111/040111-11/croi1.gif)
![croi2.gif](../images/040111/040111-11/croi2.gif)
![croi3.gif](../images/040111/040111-11/croi3.gif)
![croi4.gif](../images/040111/040111-11/croi4.gif)
![croi5.gif](../images/040111/040111-11/croi5.gif)
![croi6.gif](../images/040111/040111-11/croi6.gif)
![croi7.gif](../images/040111/040111-11/croi7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|